Kinnate Biopharma KNTE Stock
Kinnate Biopharma Price Chart
Kinnate Biopharma KNTE Financial and Trading Overview
| Kinnate Biopharma stock price | 2.65 USD |
| Previous Close | 3.16 USD |
| Open | 3.15 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 3.02 - 3.42 USD |
| 52 Week Range | 2.32 - 15.86 USD |
| Volume | 474.02K USD |
| Avg. Volume | 466.95K USD |
| Market Cap | 155.55M USD |
| Beta (5Y Monthly) | 0.185111 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.06 USD |
KNTE Valuation Measures
| Enterprise Value | -49865604 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.1928571 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.6983065 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.398 |
Trading Information
Kinnate Biopharma Stock Price History
| Beta (5Y Monthly) | 0.185111 |
| 52-Week Change | -64.31% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 15.86 USD |
| 52 Week Low | 2.32 USD |
| 50-Day Moving Average | 3.87 USD |
| 200-Day Moving Average | 6.97 USD |
KNTE Share Statistics
| Avg. Volume (3 month) | 466.95K USD |
| Avg. Daily Volume (10-Days) | 379.26K USD |
| Shares Outstanding | 46.57M |
| Float | 18.11M |
| Short Ratio | 2.02 |
| % Held by Insiders | 0.39% |
| % Held by Institutions | 93.66% |
| Shares Short | 1.67M |
| Short % of Float | 13.61% |
| Short % of Shares Outstanding | 3.59% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -26.60% |
| Return on Equity (ttm) | -44.18% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -125366000 USD |
| Net Income Avi to Common (ttm) | -122309000 USD |
| Diluted EPS (ttm) | -2.6 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 200.98M USD |
| Total Cash Per Share (mrq) | 4.32 USD |
| Total Debt (mrq) | 3.95M USD |
| Total Debt/Equity (mrq) | 1.77 USD |
| Current Ratio (mrq) | 11.308 |
| Book Value Per Share (mrq) | 4.783 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -95667000 USD |
| Levered Free Cash Flow (ttm) | -53977876 USD |
Profile of Kinnate Biopharma
| Country | United States |
| State | CA |
| City | San Francisco |
| Address | 103 Montgomery Street |
| ZIP | 94129 |
| Phone | 858 299 4699 |
| Website | https://www.kinnate.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 94 |
Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
Q&A For Kinnate Biopharma Stock
What is a current KNTE stock price?
Kinnate Biopharma KNTE stock price today per share is 2.65 USD.
How to purchase Kinnate Biopharma stock?
You can buy KNTE shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Kinnate Biopharma?
The stock symbol or ticker of Kinnate Biopharma is KNTE.
Which industry does the Kinnate Biopharma company belong to?
The Kinnate Biopharma industry is Biotechnology.
How many shares does Kinnate Biopharma have in circulation?
The max supply of Kinnate Biopharma shares is 47.17M.
What is Kinnate Biopharma Price to Earnings Ratio (PE Ratio)?
Kinnate Biopharma PE Ratio is 0.00000000 now.
What was Kinnate Biopharma earnings per share over the trailing 12 months (TTM)?
Kinnate Biopharma EPS is 0 USD over the trailing 12 months.
Which sector does the Kinnate Biopharma company belong to?
The Kinnate Biopharma sector is Healthcare.
Kinnate Biopharma KNTE included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17366.13 USD — |
-0.1
|
9.58B USD — | 17128.71 USD — | 17467.35 USD — | — - | 9.58B USD — |
| NASDAQ Global Select Market Com NQGS | 8495.19 USD — |
-0.11
|
— — | 8378.66 USD — | 8543.96 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4184.77 USD — |
+1.29
|
— — | 4144.83 USD — | 4202.15 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 931.02 USD — |
+0.81
|
— — | 921.75 USD — | 934.48 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4157.43 USD — |
+0.21
|
— — | 3927.42 USD — | 4157.43 USD — | — - | — — |
- {{ link.label }} {{link}}